Skip to main content

Drug Interactions between dabigatran and Orgovyx

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

dabigatran relugolix

Applies to: dabigatran and Orgovyx (relugolix)

GENERALLY AVOID: Concomitant use with relugolix may lead to increased plasma concentrations of substrates of the intestinal efflux transporter, P-glycoprotein (P-gp). According to the manufacturer, a relugolix dose of 40 mg may lead to saturation of intestinal P-gp. In addition, relugolix exhibits more than dose-proportional pharmacokinetics over a dose range of 10 mg to 120 mg, which may lead to increased absorption of coadministered medicines that are sensitive substrates of P-gp. However, clinical interaction studies with sensitive P-gp substrates are lacking.

MANAGEMENT: Some authorities advise that the coadministration of relugolix with sensitive substrates of P-glycoprotein, such as dabigatran etexilate, should be avoided.

References (3)
  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. (2021) "Product Information. Orgovyx (relugolix)." Myovant Sciences, Inc.
  3. (2023) "Product Information. Myfembree (estradiol/norethindrone/relugolix)." Myovant Sciences, Inc.

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer